Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acecainide pharmacokinetics in normal subjects of known acetylator phenotype.

Biopharmaceutics & drug disposition - 1 Nov 1991

Coyle J D, Boudoulas H, Lima J J

Abstract excerpt

The purpose of this study was to determine the pharmacokinetics of acecainide (formerly N-acetylprocainamide) in six normal subjects of known acetylator phenotype. Three subjects were fast acetylators and three slow acetylators by sulfapyridine phenotyping criteria. Each subject received a 20-min...

Topics

Acecainide
Acetylation
Adult
Humans
Male
Phenotype
Procainamide

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 1724922
DOI: 10.1002/bdd.2510120806

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-1724922-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acecainide pharmacokinetics in normal subjects of known acetylator phenotype.PMID 1724922Read ↗

Pharmacokinetics, acetylation-deacetylation, renal clearance, and protein binding of sulphamerazine, N4-acetylsulphamerazine, and N4-trideuteroacetylsulphamerazine in 'fast' and 'slow' acetylators.Semantic proximity Read ↗

Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators.Semantic proximity Read ↗

[Pharmacokinetics of procainamide and its metabolite depending on acetylator phenotype].Semantic proximity Read ↗

Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man.Semantic proximity Read ↗

N-acetylation phenotyping with sulphadimidine in a Turkish population.Semantic proximity Read ↗

Amantadine acetylation may be effected by acetyltransferases other than NAT1 or NAT2.Semantic proximity Read ↗

Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions.Semantic proximity Read ↗

Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers.Semantic proximity Read ↗

Acetylation phenotype in hypertensive patients.Semantic proximity Read ↗

Mesalazine pharmacokinetics and NAT2 phenotype.Semantic proximity Read ↗

N-acetylation and oxidative capacity in aged volunteers determined with sulfamethazine and antipyrine.Semantic proximity Read ↗

Paradoxical relationship between acetylator phenotype and amonafide toxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.